What Lipanthyl 200M Treats: Main Uses and Benefits

Lipanthyl 200M is primarily used to address significant symptoms related to systemic imbalance, specifically abnormal blood fat concentrations in conditions like primary hypercholesterolemia and mixed dyslipidemia. The medication is commonly used to help with elevated Total Cholesterol, LDL cholesterol, and triglycerides (TG), and may assist with low HDL cholesterol. This use may assist with managing the overall burden of cardiovascular risk factors. The adjunctive treatment is applied in addressing these risk factors when they persist despite diet and lifestyle changes. In cases of severe hypertriglyceridemia (TG 500 mg/dL), the treatment is relevant for managing the acute risk context associated with uncontrolled lipid levels.

Quick Fact: Therapeutic Focus: Managing Elevated Blood Lipids

The clinical scenarios of use often extend to individuals with Type 2 Diabetes, where managing complex lipid abnormalities is important. This application may assist with managing the risk of microvascular complications. The use of fenofibrate is relevant for addressing the chronic vascular challenges associated with diabetic dyslipidemia.

Regulatory References

1. Australian Therapeutic Goods Administration (TGA) assessment

Eligibility for Lipanthyl 200M (Fenofibrate)

Official regulatory information defines specific populations that are eligible for Lipanthyl 200M, as well as several conditions and states that restrict or prohibit its use. This medicine is approved for use in adult patients.

Populations Who Must Not Use the Medicine (Contraindications)

Fenofibrate is strictly contraindicated for patients with the following conditions, as stated in regulatory labeling:

• Severe renal impairment, including those receiving dialysis.
• Active liver disease, including primary biliary cirrhosis or unexplained persistent liver function abnormalities.
• Pre-existing gallbladder disease.
• Nursing mothers (lactation).
• Known hypersensitivity to fenofibrate, fenofibric acid, or related compounds, including prior photoallergy to fibrates or ketoprofen.

Age and Condition Restrictions

Population Group	Regulatory Status
Children and Adolescents (under 18)	Not recommended; safety and efficacy have not been established.
Older Adults (≥ 65 years)	Use is permitted, but dosage must be determined based on renal function.
Mild to Moderate Renal Impairment	Restricted use; a dose reduction or alternative medication is typically required.
Pregnancy	Not recommended; use only after a careful benefit/risk assessment.

Lipanthyl 200M (Fenofibrate) has documented interaction patterns with several medicinal product classes as established by regulatory authorities.

Co-administration with HMG-CoA Reductase Inhibitors (Statins) or other Fibrates significantly increases the risk of serious muscle toxicity, which is classified as a pharmacodynamic interaction. Similarly, combining Fenofibrate with Colchicine is also associated with a heightened risk of myopathy.

Fenofibrate may alter the exposure of other medicines. With Coumarin-type Oral Anti-coagulants (e.g., Warfarin), Fenofibrate enhances the anticoagulant effect, which can lead to a prolongation of the Prothrombin Time (PT) or International Normalized Ratio (INR). Pharmacokinetic data also show that fenofibric acid acts as a mild-to-moderate inhibitor of CYP2C9 and a weak inhibitor of CYP2C19 and CYP2A6 in vitro.

A critical constraint involves Bile-Acid Binding Resins (e.g., Cholestyramine), which interfere with fenofibrate absorption. Regulatory documents mandate a timing-based interaction rule: Fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the resin. Specific population-related notes also exist; the co-administration of Immunosuppressants (e.g., Cyclosporine) carries a heightened risk of deterioration of renal function, and muscle toxicity risk with Statins is increased in geriatric patients.

How Lipanthyl 200M Works

Fenofibrate's active component, fenofibric acid, acts as a precise pharmacological tool to modulate lipid and lipoprotein homeostasis by targeting core regulatory systems of fat metabolism. Its action is centered on transcriptional control, meaning it directly alters the rate at which cells produce the proteins necessary for fat processing and transport.

---

Agonism of the PPARalpha Receptor

This mechanism begins at the molecular level with the activation of the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha), a specialized nuclear receptor and key regulatory factor for genes governing fat metabolism. By activating this receptor, the drug initiates a signaling sequence that simultaneously increases the breakdown of fats while suppressing their production. This fundamental change in gene expression is responsible for the resulting alteration in systemic lipid and lipoprotein regulation.

---

Coordinated Regulation of Lipoprotein Clearance

PPARalpha activation leads to two complementary actions: increased production of the enzyme Lipoprotein Lipase (LPL), which accelerates the breakdown of circulating triglycerides, and suppression of Apolipoprotein C-III (Apo C-III), which normally inhibits LPL. This coordinated effort results in enhanced VLDL catabolism, serving as the primary physiological means by which plasma triglyceride concentrations are reduced.

---

Remodeling and Uricosuric Action

Beyond triglycerides, the mechanism supports a remodeling of lipoprotein composition, specifically by promoting the synthesis of proteins required for HDL and shifting LDL particles toward forms that exhibit increased affinity for hepatic clearance receptors. Separately, the active ingredient also exerts a uricosuric effect in the kidneys, leading to increased excretion of uric acid, a parallel physiological consequence.

Official Administration Guidelines for Lipanthyl 200M (Fenofibrate)

These guidelines detail the proper administration and dosage of Lipanthyl 200M.

---

Dosing and Administration

Lipanthyl 200M is formulated as a micronised capsule for oral administration. The medicine must be swallowed whole with a glass of water and must not be opened, crushed, or chewed.

Administration Rule	Detail
Route of Administration	Oral
Standard Adult Dose	Typically 200 mg once daily
Frequency	Once daily
Timing Relative to Meals	Must be taken with food (during a meal)

Taking Lipanthyl 200M with food is critical to ensure proper absorption of the fenofibrate.

---

Specific Population Instructions

Dosage adjustments are required for patients with impaired kidney function, as fenofibrate is primarily excreted by the kidneys. Use is contraindicated in cases of severe renal impairment (eGFR < 30 mL/min/1.73 m^2). For mild to moderate renal impairment, a lower dose is necessary and must be prescribed by a healthcare professional.

Fenofibrate is not recommended for use in the paediatric population (under 18 years) due to insufficient data on efficacy and safety in this age group.

---

Special Handling

If the regimen includes a bile acid binding resin, Lipanthyl 200M should be administered at least 1 hour before or 4 to 6 hours after the resin to avoid interference with absorption. If a dose is missed, patients should skip the missed dose and take the next dose at the usual time; do not double the dose to compensate.

Recent Clinical Evidence for Fenofibrate (Lipanthyl 200M)

Lipanthyl 200M, a micronized formulation of fenofibrate, is established primarily for its strong lipid-modifying effects. Clinical research consistently supports its efficacy in managing dyslipidemia, characterized by elevated triglycerides (hypertriglyceridemia) and low levels of high-density lipoprotein cholesterol (HDL-C).

---

Key Findings from Major Trials

Evidence from large-scale randomized controlled trials (RCTs), such as the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial and the ACCORD Lipid trial, has investigated the role of fenofibrate beyond its lipid-lowering properties, particularly regarding cardiovascular outcomes:

• Cardiovascular Risk: While overall results across entire study populations often did not demonstrate a significant reduction in the primary composite endpoint of major cardiovascular events, subgroup analyses identified specific patient populations who appeared to benefit. A significant reduction in cardiovascular risk was observed in patients with severe dyslipidemia—specifically, those starting treatment with both high triglyceride levels (e.g., 2.3 mmol/L) and low HDL-C levels.
• Microvascular Outcomes: The FIELD study suggested an association between fenofibrate use and a reduced rate of progression of diabetic retinopathy (eye disease) and a reduction in the need for laser intervention in individuals with type 2 diabetes. Similarly, some data suggested a protective role against kidney damage (nephropathy) in this population. These findings indicate a possible benefit on diabetes-related microvascular complications, independent of its effect on major heart disease events.

---

Real-World and Lipid Profile Effects

Real-world evidence and meta-analyses reaffirm fenofibrate's impact on the lipid profile. Studies indicate that fenofibrate treatment is typically associated with significant reductions in triglyceride levels (often by 30% to 50%) and modest increases in HDL-C levels (up to 20%). It may also shift the composition of low-density lipoprotein (LDL) particles from small, dense particles to larger, less dense particles, which is considered a less atherogenic profile.

Common questions about Lipanthyl 200M (FAQ)

Q: What is the purpose of the 'M' in Lipanthyl 200M?

A: The 'M' in Lipanthyl 200M indicates that it is a micronized formulation of the active ingredient, fenofibrate. According to official product information, the medicine is specially processed to reduce the particle size of fenofibrate. This process is intended to enhance its dissolution and optimize the way the medicine is absorbed.

---

Q: What does the doctor need to monitor when I'm on this medication?

A: Official guidelines advise that monitoring is required during fenofibrate therapy to check for potential side effects. This involves measuring liver function tests before and periodically throughout treatment. Additionally, Creatine Phosphokinase (CPK) levels should be monitored at the beginning of treatment and periodically, or if muscle pain occurs.

---

Q: Can I take Lipanthyl 200M with a statin like atorvastatin?

A: Official information regarding drug interactions advises that combining fenofibrate with HMG-CoA Reductase Inhibitors (such as statins) is associated with an increased risk of serious muscle toxicity. Consultation with a healthcare professional is necessary to evaluate the risks and benefits of co-administration and to determine if this combination is appropriate.

---

Q: How long will it take for Lipanthyl 200M to start working?

A: The full therapeutic effect is not instantaneous. Regulatory documents state that the medicine's effectiveness is typically assessed using repeat lipid level measurements, often taken at intervals of 4 to 8 weeks after starting treatment. After two months, the necessity for continued treatment is typically reviewed if an adequate response has not been achieved.

---

Q: What should I do with my expired or unused Lipanthyl 200M capsules?

A: Official guidance, such as from the FDA, recommends using an authorized drug take-back program for safe disposal of unused or expired medicine. If a take-back program is unavailable, official guidance suggests mixing the medicine with an unappealing substance, placing it in a sealed container, and discarding it in the trash. Medications should generally not be flushed down the toilet unless specified on a regulatory list.

---

Q: Does Lipanthyl 200M treat high cholesterol or high triglycerides?

A: According to official indications, fenofibrate is used to treat both high triglyceride levels and elevated low-density lipoprotein cholesterol (LDL-C). It is indicated as an addition to diet to help manage unhealthy fat levels in the blood, addressing both components of dyslipidemia.

---

Q: Is it safe to drink alcohol while taking fenofibrate?

A: Official safety information advises that heavy alcohol use should be limited or avoided during treatment. This precaution is recommended because excessive alcohol consumption carries an independent risk of liver problems and pancreatitis, conditions that are also potential serious side effects associated with fenofibrate.

How to Store and Dispose of Lipanthyl 200M?

Lipanthyl 200M (fenofibrate) must be stored correctly to maintain its effectiveness. Keep the capsules in their original packaging and store them at a controlled room temperature, typically below 30°C (86°F). Ensure the medication is kept out of the reach and sight of children and pets, as accidental ingestion can be dangerous.

To dispose of unused or expired Lipanthyl 200M, do not flush it down the toilet or pour it down a drain, as this can harm the environment, particularly aquatic life. Do not dispose of it in household trash. Instead, check with your local pharmacy or waste disposal service for authorized drug take-back programs. These programs ensure safe and environmentally sound disposal in accordance with local regulatory requirements.